The company is pleased to report positive performances from all divisions this quarter. Growth in our research divisions, Discovery Services and the Dedicated Centres was solid
Spiro will be responsible for the overall strategy, implementation and growth of Lupin’s U.S. Generics business
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery
He has over two decades of rich experience in management consulting, advising and transforming leading generic pharmaceutical companies in India and global markets
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
The capital expansion program commenced in June 2022 and is expected to complete in 2024
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Lacosamide Injection is used to treat partial-onset seizures.
The company has a total sales of Rs. 25.8 crore during FY 21-22 and Rs. 26.4 crore during FY 20-21.
Subscribe To Our Newsletter & Stay Updated
